Related Experiment Videos
Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy
D E Dupuy1, J M Monchik, C Decrea
1Department of Diagnostic Imaging, Division of Endocrine Surgery and Pathology, Brown Medical School, Rhode Island Hospital, Providence, RI 02903, USA.
Surgery
|December 14, 2001
Summary
Radiofrequency ablation (RFA) offers a promising new treatment for recurrent well-differentiated thyroid cancer (WTC). This minimally invasive ultrasound-guided procedure effectively treated local WTC recurrence with no major complications.
Area of Science:
- Oncology
- Interventional Radiology
- Endocrinology
Background:
- Regional recurrence of well-differentiated thyroid cancer (WTC) is typically managed with surgery.
- Radiofrequency ablation (RFA) is an established treatment for liver tumors, offering a less invasive alternative.
- The study explored RFA's application for locally recurrent WTC.
Purpose of the Study:
- To evaluate the safety and efficacy of ultrasound-guided radiofrequency ablation (RFA) for treating locally recurrent well-differentiated thyroid cancer (WTC).
Main Methods:
- Eight patients with biopsy-proven recurrent WTC underwent percutaneous RFA under conscious sedation and ultrasound guidance.
- The RF electrode was inserted into the recurrent tumor site and treated for 2-12 minutes.
- Follow-up included ultrasound, thyroglobulin levels, biopsy, and surgical intervention when necessary.
Main Results:
- All patients were treated as outpatients with no bleeding or infectious complications.
- One case of vocal cord paralysis and a minor skin burn were reported.
- No local recurrence was detected at a mean follow-up of 10.3 months, with imaging showing tumor shrinkage and decreased vascularity.
Conclusions:
- Ultrasound-guided RFA is a safe and effective new treatment option for locally recurrent WTC.
- This modality shows potential for future use in managing recurrent thyroid cancer.
- RFA may offer a valuable alternative to surgery for select patients.